Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis

被引:44
作者
Wen, Yong Hannah
Koeppen, Hartmut
Garcia, Roberto
Chiriboga, Luis
Tarlow, Branden D.
Peters, Brock A.
Eigenbrot, Charles
Yee, Herman
Steiner, German
Greco, M. Alba [1 ]
机构
[1] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
[2] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA
[4] Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA
[5] NYU, Hosp Joint Dis, Dept Pathol, New York, NY 10003 USA
关键词
EGFR; immunohistochemistry; mutation; osteosarcoma;
D O I
10.1016/j.humpath.2007.01.002
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Activation of intracellular mitogenic signal transduction pathways driven by the ErbB family of receptor tyrosine kinases has been implicated in the development and/or progression of a variety of cancers. Studies on ErbB receptors in osteosarcoma have focused on HER-2 and have produced conflicting results with few studies evaluating the expression of the epidermal growth factor receptor (EGFR). In this study, we determined the level of expression of EGFR and the mutational status of the EGFR receptor in a subset of osteosarcoma tumor samples as well as in a series of established bone tumor-derived cell lines. EGFR protein expression was detected in the form of strong membranous staining by immunohistochemistry in 21 (57%) of 37 cases analyzed. Six of 12 (50%) osteosarcoma cell lines revealed moderate to high expression levels of EGFR. Two somatic alterations (E829E and R831C) were identified in the cytoplasmic domain of the EGFR gene in 1 of 10 tumor samples. The significance of these findings for the pathobiology of osteosarcomas will be investigated further. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1184 / 1191
页数:8
相关论文
共 34 条
[1]   ErbB2 expression is correlated with increased survival of patients with osteosarcoma [J].
Akatsuka, T ;
Wada, T ;
Kokai, Y ;
Kawaguchi, S ;
Isu, K ;
Yamashiro, K ;
Yamashita, T ;
Sawada, N ;
Yamawaki, S ;
Ishii, S .
CANCER, 2002, 94 (05) :1397-1404
[2]   Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas [J].
Anninga, JK ;
van de Vijver, MJ ;
Cleton-Jansen, AM ;
Kristel, PMP ;
Taminiau, AHM ;
Nooij, M ;
Egeler, RM ;
Hogendoorn, PCW .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (07) :963-970
[3]  
[Anonymous], NAT REV DRUG DISC SU
[4]  
EDERHARD DA, 2005, J CLIN ONCOL, V23, P5900
[5]   Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue [J].
Fellenberg, J ;
Krauthoff, A ;
Pollandt, K ;
Delling, G ;
Parsch, D .
LABORATORY INVESTIGATION, 2004, 84 (01) :113-121
[6]   Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma [J].
Ferrari, S ;
Bertoni, F ;
Zanella, L ;
Setola, E ;
Bacchini, P ;
Alberghini, M ;
Versari, M ;
Bacci, G .
CANCER, 2004, 100 (09) :1936-1942
[7]   Expression of HER2/erbB-2 correlates with survival in osteosarcoma [J].
Gorlick, R ;
Huvos, AG ;
Heller, G ;
Aledo, A ;
Beardsley, GP ;
Healey, JH ;
Meyers, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2781-2788
[8]   Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [J].
Hidalgo, M ;
Siu, LL ;
Nemunaitis, J ;
Rizzo, J ;
Hammond, LA ;
Takimoto, C ;
Eckhardt, SG ;
Tolcher, A ;
Britten, CD ;
Denis, L ;
Ferrante, K ;
Von Hoff, DD ;
Silberman, S ;
Rowinsky, EK .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3267-3279
[9]   Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma [J].
Hughes, DPM ;
Thomas, DG ;
Giordano, TJ ;
Baker, LH ;
McDonagh, KT .
CANCER RESEARCH, 2004, 64 (06) :2047-2053
[10]   ERBB receptors and cancer: The complexity of targeted inhibitors [J].
Hynes, NE ;
Lane, HA .
NATURE REVIEWS CANCER, 2005, 5 (05) :341-354